Shots:
- Endogenex has reported REGENT-1 Australian study data of ReCET System for the treatment of inflamed & dysfunctional tissue associated with type 2 diabetic (T2D) duodenopathy; REGENT-1 is also being conducted in the US
- The study showed dose-responsive improvements in insulin sensitivity & beta cell function at 12wks., sustained through 48wks., with 100% procedural success & no serious device or procedure-related adverse events; data was presented at DDW 2025
- ReCET System is an endoscopic outpatient procedure that uses non-thermal energy to regenerate healthy cells in the mucosal & submucosal layers of the duodenum for the treatment of inflamed & dysfunctional tissue linked with T2D duodenopathy
Ref: Globenewswire| Image: Endogenex
Related News:- OcuSciences’ OcuMet Beacon Receives the US FDA Clearance for Retinal Health Assessment
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click Here for the Full Press Release
